# TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

> **NCT00523926** · PHASE2 · COMPLETED · sponsor: **Tibotec BVBA** · enrollment: 75 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** TMC207

## Key facts

- **NCT ID:** NCT00523926
- **Lead sponsor:** Tibotec BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2012-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523926, "TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00523926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*